Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Corbus Pharmaceuticals Holdings's Operating Income for the three months ended in Dec. 2023 was $-10.10 Mil. Corbus Pharmaceuticals Holdings's Interest Expense for the three months ended in Dec. 2023 was $-0.71 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Interest Coverage or its related term are showing as below:

CRBP's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Corbus Pharmaceuticals Holdings Interest Coverage Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Corbus Pharmaceuticals Holdings Interest Coverage Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

N/A

Corbus Pharmaceuticals Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Corbus Pharmaceuticals Holdings's Interest Coverage

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Interest Coverage falls into.

Corbus Pharmaceuticals Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Corbus Pharmaceuticals Holdings's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Corbus Pharmaceuticals Holdings's Interest Expense was $-2.92 Mil. Its Operating Income was $-45.08 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.24 Mil.

Corbus Pharmaceuticals Holdings did not have earnings to cover the interest expense.

Corbus Pharmaceuticals Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Corbus Pharmaceuticals Holdings's Interest Expense was $-0.71 Mil. Its Operating Income was $-10.10 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.24 Mil.

Corbus Pharmaceuticals Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Corbus Pharmaceuticals Holdings (NAS:CRBP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Corbus Pharmaceuticals Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Executives

Yong Ben	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer	director	500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen	director, officer: Chief Executive Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian	officer: Chief Commercial Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran	officer: Chief Financial Officer	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake	officer: Chief Scientific Officer	21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White	officer: Chief Medical Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia	officer: Chief Operating Officer	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman	director	15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062